Latest Headlines

Latest Headlines

Merck, Sanofi granted European Commission thumbs-up on Gardasil 9

Following behind a blockbuster is no easy task, but with a European Commission decision on Wednesday in favor of the vaccine, Merck's Gardasil 9 may just be up to the challenge of succeeding Gardasil.

One dose of GlaxoSmithKline's Cervarix may suffice

The recommended schedule for HPV vaccination is two or three doses, but some patients never make it back for all of the shots. This may cease to be a concern if future trials prove what scientists reported on Wednesday: A single dose of GlaxoSmithKline's Cervarix could work as well as the recommended two- or three-dose regimens at preventing the majority of cervical cancers.

Healthcare systems could benefit from covering HPV vaccine in boys, study says

A new analysis shows that healthcare systems can prevent throat cancer cases and save in long-term treatment costs by covering the HPV vaccine in young boys. Currently, Australia, Canada and the United States recommend the jab for boys, but only cover it for young girls.

Sanofi, Merck win EMA nod for Gardasil 9

Merck's new-and-improved Gardasil is making headway in Europe with the word late last week that the European Medicines Agency has recommended the jab against 9 types of human papillomavirus and will send its blessing to the European Commission.

Canadian paper backpedals from Gardasil side effects story

Merck has already had its fair share of struggles with uptake rates for its HPV vaccine, Gardasil. A Toronto Star story from earlier this month, which focused on young women who'd suffered serious problems following vaccination, didn't help matters. The paper has since backed away from its story, but some damage may already be done.

Serum threatens Merck's Gardasil with low-cost competitor

Serum Institute of India, which has a history of undercutting its competition in the vaccine sphere, is expanding this undercutting game to HPV. Its low-cost competitor to Merck's Gardasil could hit the market in late 2018 at one-third the price.

Serum Institute of India poses challenge to Merck HPV vaccine

The Serum Institute of India, the world's fifth largest vaccinemaker by volume, is eyeing newer vaccines, including one for the human papillomavirus expected to be launched by late 2018 and sell at a third of the price of Merck & Co.'s blockbuster Gardasil, Bloomberg reported.

No link between Merck's Gardasil and MS risk, study shows

Merck and partner Sanofi can breathe easy: According to a new study, their blockbuster Gardasil isn't linked to an increased risk of multiple sclerosis.

New study clears Merck's blockbuster Gardasil of MS risk

Good news for Merck: According to a new study, its cash cow vaccine, HPV-blocker Gardasil, isn't linked to an increased risk of multiple sclerosis--or any other similar CNS diseases, for that matter.

Merck's next-gen Gardasil wins FDA approval

Merck's Gardasil follow-up is here, meaning blockbuster sales are likely on the way. But they'll come at the expense of the previous iteration.